Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: A case report

Tumori

Volumn 94, Issue 6, 2008, Pages 849-852

  Pedersini, Rebecca ^a,b   Vattemi, Emanuela ^a   Lusso, Maria Rita ^a   Mazzoleni, Guido ^a   Ebner, Heinrich ^a   Graiff, Claudio ^a  

^a Central Hospital   (Italy)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

EGFR; Erlotinib; Malignant thymoma; Target therapy

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; RECEPTOR UPREGULATION; RECURRENT CANCER; THYMUS CANCER;

EID: 61349086690     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400613     Document Type: Article

References (20)

1. Azarow KS, Pearl RH, Zurcher R, Edwards FH, Cohen AJ: Primary mediastinal masses: a comparison of adult and pediatric populations. J Thorac Cardiovasc Surg Cancer, 106: 67-72, 1993.
2. Papapopoulos KP, Thomas CR: Current chemotherapy options for thymic epithelial neoplasm. Expert Opin Pharmacother, 6: 1169-1177, 2005.
3. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F, Bevilacqua G: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer, 31: 178-183, 1995.
4. Issing WJ, Liebich C, WustrowTP, Ullrich A: Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res, 16: 283-288, 1996.
5. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res, 66: 1640-1647, 2006.
6. Henley JD, Cummings OW, Loehrer PJ: Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol, 130: 222-224, 2004.
7. Henley JD, Koukoulis GK, Loehrer PJ: Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol, 128: 167-170, 2002.
8. Hayashi Y, Ishii N, Obayashi C, Jinnai K, Hanioka K, Imai Y, Itoh H: Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch, 426: 43-50, 1995.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L: Erlotinib in previously treated non small cell lung cancer. N Engl J Med, 353: 123-133, 2005.
10. Umemura S, SegawaY, Fujiwara K, Takata I, Seki N, Tokuda Y, Eguchi K, Mandai K: A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol, 32: 262-265, 2002.
11. Takamizawa A, Koizumi T, Kubo K, Sekiguchi M, Honda T: A case of relapsed thymic carcinoma that responded remarkably to chemotherapy with CPT-11. Gan To Kagaku Ryoho, 25: 2115-2118, 1998.
12. Loehrer PJ Sr, Wang W, Johnson DH, Aisner SC, Ettinger DS: Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. J Clin Oncol, 22: 293-299, 2004.
13. Palmieri G, Marino M, Salvatore M, Budillon A, Mao G, Caraglia M, Montella L: Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci, 12: 757-761, 2007.
14. Kurup A, Burns M, Drop cho S, Pao W, Loehrer PJ: Phase II study of gefinitib treatment in advanced thymic malignancies. J Clin Oncol (ASCO Annual Meeting Proc), 23 (suppl 16): 7068 (abstr), 2005.
15. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A: Response of thymoma to cetuximab. Lancet Oncol, 8: 449-450, 2007.
16. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351: 337-345, 2004.
17. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. J Clin Oncol (ASCO Annual Meeting Proc), 22 (suppl 14): 3511 (abstr), 2004.
18. Tsao MS, Sakurada A, Lorimer I, Cutz J, Kamel-Reid S, Squire J, Ding K, Frank R, Seymour L, Shepherd F: Molecular analysis of the epidermal growth factor receptor (EGFR) gene and protein expression in patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. J Clin Oncol (ASCO Annual Meeting Proc), 23 (suppl 16): 7007 (abstr), 2005.
19. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol, 22: 4772-4778, 2004.
20. Gill GN, Bertics PJ, Santon JB: Epidermal growth factor and its receptor. Mol Cell Endocrinol, 51: 169-186, 1987.